146 related articles for article (PubMed ID: 38878003)
1. Efficacy and safety of adoptive T-cell therapy in treating cytomegalovirus infections post-haematopoietic stem cell transplantation: A systematic review and meta-analysis.
Taherian MR; Azarbar P; Barkhordar M; Toufani S; Aliabadi LS; Bahri T; Ahmadvand M; Yaghmaie M; Daneshvar A; Vaezi M
Rev Med Virol; 2024 Jul; 34(4):e2558. PubMed ID: 38878003
[TBL] [Abstract][Full Text] [Related]
2. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
3. Adoptive therapy with cytomegalovirus-specific cytotoxic T lymphocytes for refractory cytomegalovirus DNAemia and disease after allogeneic haematopoietic stem cell transplantation.
Jiang Z; Fan Z; Zhang T; Lin R; Xu H; Xu N; Huang F; Chi P; Ou X; Wang Z; Liu H; Zhao K; Jiang L; Yu S; Sun J; Liu Q; Xuan L
Br J Haematol; 2024 Apr; 204(4):1393-1401. PubMed ID: 38168845
[TBL] [Abstract][Full Text] [Related]
4. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
6. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.
Maffini E; Giaccone L; Festuccia M; Brunello L; Busca A; Bruno B
Expert Rev Hematol; 2016 Jun; 9(6):585-96. PubMed ID: 27043241
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
8. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
Liu J; Kong J; Chang YJ; Chen H; Chen YH; Han W; Wang Y; Yan CH; Wang JZ; Wang FR; Chen Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Clin Microbiol Infect; 2015 Dec; 21(12):1121.e9-15. PubMed ID: 26093077
[TBL] [Abstract][Full Text] [Related]
9. [Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation].
Xu Z; Huang X; Sun Y; Wang F; Yan C; Zhang X; Han W; Chen Y; Wang J; Chen H; Wang Y; Zhang Y; Liu K; Xu L
Zhonghua Nei Ke Za Zhi; 2015 Feb; 54(2):101-5. PubMed ID: 25907838
[TBL] [Abstract][Full Text] [Related]
10. The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis.
Chuleerarux N; Nematollahi S; Thongkam A; Dioverti MV; Manothummetha K; Torvorapanit P; Langsiri N; Worasilchai N; Plongla R; Chindamporn A; Sanguankeo A; Permpalung N
Clin Microbiol Infect; 2022 Mar; 28(3):332-344. PubMed ID: 34752926
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis.
Giménez E; Torres I; Albert E; Piñana JL; Hernández-Boluda JC; Solano C; Navarro D
Am J Transplant; 2019 Sep; 19(9):2479-2494. PubMed ID: 31247126
[TBL] [Abstract][Full Text] [Related]
12. Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution.
Smith C; Brennan RM; Tey SK; Smyth MJ; Burrows SR; Miles JJ; Hill GR; Khanna R
J Virol; 2016 Aug; 90(16):7497-507. PubMed ID: 27279616
[TBL] [Abstract][Full Text] [Related]
13. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
14. Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant.
Sutrave G; Blyth E; Gottlieb DJ
Cytotherapy; 2017 Nov; 19(11):1284-1301. PubMed ID: 28927824
[TBL] [Abstract][Full Text] [Related]
15. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
16. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
[TBL] [Abstract][Full Text] [Related]
17. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Ma CKK; Clancy L; Simms R; Burgess J; Deo S; Blyth E; Micklethwaite KP; Gottlieb DJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):71-77. PubMed ID: 28864137
[TBL] [Abstract][Full Text] [Related]
19. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
[TBL] [Abstract][Full Text] [Related]
20. Control of Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on CMV-Specific T Cell Reconstitution.
van der Heiden P; Marijt E; Falkenburg F; Jedema I
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1776-1782. PubMed ID: 29626514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]